out-licensing
BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus
BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge
Actionable Insights Powered by AI
BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge